GlassScriptPhysician profile
Laura R Daniel
NPI 1952634248
$3,646.93
in general payments reported to CMS, 2019-2025
27 companies · $562 in 2025
The $562 reported for 2025 was more than what 75% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $746 · 2022: $885 · 2023: $750 · 2024: $704 · 2025: $562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,016.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,016.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $832.64 | 2021-2025 | |
| Glaxosmithkline, LLC. | $783.73 | 2021-2025 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $491.87 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $205.34 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $184.18 | 2021-2025 | Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $158.56 | 2021-2024 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $127.91 | 2022 | |
| Pfizer INC. | $106.43 | 2021-2023 | |
| Neurocrine Biosciences, INC. | $90.08 | 2023-2025 | Ingrezza |
| Lundbeck LLC | $89.77 | 2024-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $66.61 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $60.73 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $59.29 | 2024-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $43.67 | 2021-2022 | |
| Alkermes, INC. | $39.70 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $38.26 | 2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $37.47 | 2022 | |
| Axsome Therapeutics, INC. | $35.68 | 2023 | Auvelity |
| Amgen INC. | $29.62 | 2021-2025 | Repatha, Otezla |
| Philips North America LLC | $26.16 | 2022-2024 | (Cm9) Amb Mon & Diag Und |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.45 | 2024 | Xifaxan |
| Astellas Pharma US INC | $22.29 | 2025 | Vyloy |
| Edwards Lifesciences Corporation | $22.15 | 2024 | |
| Janssen Pharmaceuticals, INC | $19.21 | 2021 | |
| Xeris Pharmaceuticals, INC. | $18.17 | 2024 | Gvoke Hypopen |
| Dexcom, INC. | $17.01 | 2023 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $15.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.